Abbott Laboratories Competitors

Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has raised its dividend for 24 consecutive years and Abbott Laboratories has raised its dividend for 1 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Medtronic and Abbott Laboratories, as reported by MarketBeat.

Medtronic presently has a consensus target price of $117.8571, suggesting a potential upside of 7.90%. Abbott Laboratories has a consensus target price of $114.3333, suggesting a potential upside of 7.93%. Given Abbott Laboratories' higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Medtronic.

Risk & Volatility

Medtronic has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Medtronic and Abbott Laboratories' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Medtronic and Abbott Laboratories' gross revenue, earnings per share (EPS) and valuation.

Medtronic has higher earnings, but lower revenue than Abbott Laboratories. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 73.1% of Abbott Laboratories shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Abbott Laboratories and Intuitive Surgical's net margins, return on equity and return on assets.

Volatility and Risk

Abbott Laboratories has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Insider & Institutional Ownership

73.1% of Abbott Laboratories shares are held by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Abbott Laboratories and Intuitive Surgical's gross revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Intuitive Surgical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Intuitive Surgical, as provided by MarketBeat.com.

Abbott Laboratories presently has a consensus price target of $114.3333, suggesting a potential upside of 7.93%. Intuitive Surgical has a consensus price target of $720.4737, suggesting a potential downside of 1.10%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Abbott Laboratories on 7 of the 13 factors compared between the two stocks.

Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Stryker and Abbott Laboratories' gross revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Stryker. Stryker is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Abbott Laboratories' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Stryker and Abbott Laboratories, as reported by MarketBeat.

Stryker presently has a consensus target price of $220.68, indicating a potential downside of 0.10%. Abbott Laboratories has a consensus target price of $114.3333, indicating a potential upside of 7.93%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Stryker.

Insider and Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 73.1% of Abbott Laboratories shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Stryker pays out 27.8% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 1 consecutive years and Abbott Laboratories has raised its dividend for 1 consecutive years.

Summary

Abbott Laboratories beats Stryker on 9 of the 17 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Volatility & Risk

Becton, Dickinson and has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Profitability

This table compares Becton, Dickinson and and Abbott Laboratories' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Becton, Dickinson and and Abbott Laboratories, as reported by MarketBeat.com.

Becton, Dickinson and presently has a consensus target price of $280.8571, suggesting a potential upside of 18.81%. Abbott Laboratories has a consensus target price of $114.3333, suggesting a potential upside of 7.93%. Given Becton, Dickinson and's higher possible upside, research analysts plainly believe Becton, Dickinson and is more favorable than Abbott Laboratories.

Earnings & Valuation

This table compares Becton, Dickinson and and Abbott Laboratories' revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

84.2% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 73.1% of Abbott Laboratories shares are held by institutional investors. 0.1% of Becton, Dickinson and shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dividends

Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.3%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Becton, Dickinson and pays out 27.1% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and has increased its dividend for 10 consecutive years and Abbott Laboratories has increased its dividend for 1 consecutive years.

Summary

Abbott Laboratories beats Becton, Dickinson and on 11 of the 18 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Institutional & Insider Ownership

73.1% of Abbott Laboratories shares are held by institutional investors. Comparatively, 90.2% of Boston Scientific shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Abbott Laboratories has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Abbott Laboratories and Boston Scientific, as provided by MarketBeat.

Abbott Laboratories currently has a consensus target price of $114.3333, suggesting a potential upside of 7.93%. Boston Scientific has a consensus target price of $45.00, suggesting a potential upside of 21.13%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Boston Scientific's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Abbott Laboratories and Boston Scientific's revenue, earnings per share (EPS) and valuation.

Boston Scientific has lower revenue, but higher earnings than Abbott Laboratories. Boston Scientific is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Abbott Laboratories on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Insider & Institutional Ownership

79.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 73.1% of Abbott Laboratories shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Edwards Lifesciences has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Abbott Laboratories' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Edwards Lifesciences and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Edwards Lifesciences and Abbott Laboratories, as reported by MarketBeat.

Edwards Lifesciences currently has a consensus target price of $86.0526, suggesting a potential upside of 2.92%. Abbott Laboratories has a consensus target price of $114.3333, suggesting a potential upside of 7.93%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than Edwards Lifesciences.